Free NHS SCN1A testing confirms 75% of UK Dravet diagnoses, feeding a NICE-sequenced cannabidiol-then-fenfluramine treatment algorithm.

Dravet syndrome is a severe, genetically defined developmental and epileptic encephalopathy, with de novo SCN1A pathogenic variants confirmed in an estimated 80% to 90% of UK cases and clinical molecular confirmation running at roughly 75%. An estimated 400 to 500 patients live with Dravet syndrome in the UK. The NHS Genomic Medicine Service offers SCN1A testing free of charge as part of an epilepsy gene panel to any patient presenting with febrile-seizure-onset epilepsy, with a standard turnaround of 8 to 16 weeks and a fast-track route of under 2 weeks for infantile encephalopathy presentations.

Management runs on a NICE-defined sequence rather than physician discretion: valproate and clobazam first, with sodium-channel blockers contraindicated and documented, then cannabidiol, Epidiolex, NICE TA614 from 2019, added and reassessed at 12 weeks, then fenfluramine, Fintepla, NICE TA887 from 2022, added for inadequate responders. Both agents require prescription through one of 25 NHS Highly Specialised Service paediatric epilepsy centres, and fenfluramine carries a mandatory cardiac monitoring obligation, the Fintepla Cardiac Monitoring Scheme. SUDEP risk of 2% to 18% lifetime is a structural feature of NHS management: NICE guideline NG217 mandates a SUDEP risk discussion at every epilepsy review.

Treatment sequence here follows NICE guidance, not physician discretion.

Five questions this report answers:

Q1 - How does the NHS GMS free SCN1A gene panel shape UK Dravet diagnosis rates?

Q2 - What does the NICE TA614/TA887 cannabidiol-then-fenfluramine sequence mean for positioning a new therapy?

Q3 - How does SUDEP risk factor into UK Dravet commercial and medical-affairs planning?

Q4 - Where is the unmet need in the UK Dravet syndrome treatment pathway?

Q5 - What cardiac monitoring obligation applies to fenfluramine under the Fintepla Cardiac Monitoring Scheme?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #NICE #NHS #Epilepsy #UKHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/dravet-syndrome/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/